Oct 2026· Journal of Clinical Medicine of Kazakhstan· 0 citations· 11 references
TL;DR
Failure to achieve a sustained virologic response was associated with greater biochemical activity, more advanced liver fibrosis, longer disease duration, genotype 3 infection, and lower treatment adherence.
Abstract
Introduction: Direct-acting antiviral therapy achieves high cure rates in chronic hepatitis C; however, a minority of patients do not achieve a sustained virologic response. The aim of this study was to evaluate clinical, demographic, and virologic factors associated with failure to achieve a sustained virologic response among patients with chronic hepatitis C treated in the Turkestan Region of Kazakhstan.
Methods: We performed a retrospective case-control study of 168 adults treated with direct-acting antivirals between January 2018 and December 2022. The control group comprised 126 patients who achieved a sustained virologic response, and the case group comprised 42 patients without a sustained virologic response. Demographic characteristics, disease duration, treatment duration, adherence, hepatitis C virus genotype, pretreatment alanine aminotransferase level, liver elastography, and fibrosis stage were analyzed.
Results: Patients without a sustained virologic response had higher pretreatment alanine aminotransferase levels (p=0.03), higher liver stiffness values on elastography (p=0.007), and a longer duration of chronic hepatitis C before treatment (p<0.0001). Genotype 3 was more frequent among cases than controls (59.5% vs 24.6%; p<0.0001), and F4 fibrosis was also more common (40.5% vs 10.3%; p<0.0001). Treatment duration greater than 12 weeks (p=0.02) and lower treatment adherence (p<0.0001) were more frequent in the case group. Age, sex, ethnicity, and previous pegylated interferon/ribavirin therapy did not differ significantly between groups.
Conclusion: Failure to achieve a sustained virologic response was associated with greater biochemical activity, more advanced liver fibrosis, longer disease duration, genotype 3 infection, and lower treatment adherence. Adherence represents a potentially modifiable factor that may be addressed through structured follow-up and patient counseling.
A subset of patients exhibits persistent infection despite therapy, underscoring the need for improved antiviral strategies and individualized management.
A. Killer, Elisa Hellendahl, S. Gliga et al.· Infection· 0 citations
This case shows immune checkpoint inhibition can reverse immune tolerance of chronic HCV and can achieve SVR without DAAs, and suggests that ICI may restore anti-viral immunity in chronic infections and has implications for treatment decisions for HCV.
A. Abdulhamid· Case Reports in Gastroentero...· 0 citations
The aim of this study was to evaluate virological response, biochemical changes, and treatment tolerability in patients with chronic hepatitis C receiving pangenotypic direct-acting antiviral (DAA) therapy. The study included patients with chronic hepatitis C virus infection followed at a tertiary care center between 2...
Berfin Çirkin Doruk, M. Uğuz· Medicine· 0 citations
BACKGROUND
Hepatitis E virus (HEV) affects immunocompromised individuals. Unlike immunocompetent hosts, who rarely develop chronic infection, up to two-thirds of immunocompromised patients progress to chronicity. Ribavirin is the recommended antiviral therapy, yet predictors of sustained virological response (SVR) rema...
G. Roo-Brand, E. Verschuuren, M. Knoester et al.· Journal of Clinical Virology· 1 citation
Objective: Hepatitis A is an acute infection of liver caused by the hepatitis A virus (HAV), a non-enveloped RNA virus of the Picornaviridae family. It can present with a wide spectrum of severity, from asymptomatic seroconversion to fulminant hepatic failure, due to its high transmissibility and the persistent challen...
Lalit Seju, Lipika Maru, Prerna Vaishnav· International Journal of Cur...· 0 citations